Author: Patrick van der Valk

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to… Read more »

RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Aetion’s initiative will focus on better… Read more »

XCELSIOR registry showcases its power in using real-world datasets and clinical outcomes to aid decision-making and treatment options for CNS cancer patients. [EIN Presswire] Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of… Read more »

Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries. EINPressWire, 11/8/22 Last month, the 21st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format. In… Read more »

xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to… Read more »

Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol. xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse… Read more »

xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study.… Read more »